8-31-2017

Increasing Use of Allogeneic Hematopoietic Cell Transplantation in Patients Aged 70 Years and Older in the United States

Lori Muffly
Stanford University

Marcelo C. Pasquini
Medical College of Wisconsin

Michael Martens
Medical College of Wisconsin

Ruta Brazauskas
Medical College of Wisconsin

Xiaochun Zhu
Medical College of Wisconsin

Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub

Part of the [Diseases Commons](#), and the [Internal Medicine Commons](#)

See next page for additional authors

[Right click to open a feedback form in a new tab to let us know how this document benefits you.](#)

Repository Citation

Muffly, Lori; Pasquini, Marcelo C.; Martens, Michael; Brazauskas, Ruta; Zhu, Xiaochun; Adekola, Kehinde; Aljurf, Mahmoud; Ballen, Karen K.; Bajel, Ashish; Baron, Frederic; Battiwalla, Minoo; Beitinjane, Amer; Cahn, Jean-Yves; Carabasi, Mathew; Chen, Yi-Bin; Chhabra, Saurabh; Ciurea, Stefan; Copelan, Edward; D'Souza, Anita; Edwards, John; Foran, James; Freytes, Cesar O.; Fung, Henry C.; Gale, Robert Peter; Giralt, Sergio; Hashmi, Shahrukh K.; Hildebrandt, Gerhard C.; Ho, Vincent; Jakubowski, Ann; and Lazarus, Hillard, "Increasing Use of Allogeneic Hematopoietic Cell Transplantation in Patients Aged 70 Years and Older in the United States" (2017). *Internal Medicine Faculty Publications*. 165.
https://uknowledge.uky.edu/internalmedicine_facpub/165

This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Increasing Use of Allogeneic Hematopoietic Cell Transplantation in Patients Aged 70 Years and Older in the United States

Digital Object Identifier (DOI)

<https://doi.org/10.1182/blood-2017-03-772368>

Notes/Citation Information

Published in *Blood*, v. 130, no. 9, p. 1156-1164.

This research was originally published in *Blood*. Lori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K. Ballen, Ashish Bajel, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O. Freytes, Henry C. Fung, Robert Peter Gale, Sergio Giral, Shahrukh K. Hashmi, Gerhard C. Hildebrandt, Vincent Ho, Ann Jakubowski, Hillard Lazarus, Marlise R. Luskin, Rodrigo Martino, Richard Maziarz, Philip McCarthy, Taiga Nishihori, Rebecca Olin, Richard F. Olsson, Attaphol Pawarode, Edward Peres, Andrew R. Rezvani, David Rizzieri, Bipin N. Savani, Harry C. Schouten, Mitchell Sabloff, Matthew Seftel, Sachiko Seo, Mohamed L. Sorrow, Jeff Szer, Baldeep M. Wirk, William A. Wood and Andrew Artz. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. *Blood*. 2017;130:1156-1164. © the American Society of Hematology.

The copyright holder has granted the permission for posting the article here.

Due to the large number of authors, only the first 30 and the authors affiliated with the University of Kentucky are listed in the author section above. For the complete list of authors, please download this article or visit: <https://doi.org/10.1182/blood-2017-03-772368>

Authors

Lori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K. Ballen, Ashish Bajel, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O. Freytes, Henry C. Fung, Robert Peter Gale, Sergio Giral, Shahrukh K. Hashmi, Gerhard C. Hildebrandt, Vincent Ho, Ann Jakubowski, and Hillard Lazarus

TRANSPLANTATION

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Lori Muffy,¹ Marcelo C. Pasquini,² Michael Martens,³ Ruta Brazauskas,^{2,3} Xiaochun Zhu,² Kehinde Adekola,⁴ Mahmoud Aljurf,⁵ Karen K. Ballen,⁶ Ashish Bajel,⁷ Frederic Baron,⁸ Minoo Battiwalla,⁹ Amer Beitinjaneh,¹⁰ Jean-Yves Cahn,¹¹ Mathew Carabasi,¹² Yi-Bin Chen,¹³ Saurabh Chhabra,¹⁴ Stefan Ciurea,^{15,16} Edward Copelan,¹⁷ Anita D'Souza,² John Edwards,¹⁸ James Foran,¹⁹ Cesar O. Freytes,²⁰ Henry C. Fung,²¹ Robert Peter Gale,²² Sergio Giralt,²³ Shahrukh K. Hashmi,^{24,25} Gerhard C. Hildebrandt,²⁶ Vincent Ho,²⁷ Ann Jakubowski,²³ Hillard Lazarus,²⁸ Marlise R. Luskin,²⁹ Rodrigo Martino,³⁰ Richard Maziarz,³¹ Philip McCarthy,³² Taiga Nishihori,³³ Rebecca Olin,³⁴ Richard F. Olsson,^{35,36} Attaphol Pawarode,³⁷ Edward Peres,³⁸ Andrew R. Rezvani,¹ David Rizzieri,³⁹ Bipin N. Savani,⁴⁰ Harry C. Schouten,⁴¹ Mitchell Sabloff,⁴² Matthew Seftel,⁴³ Sachiko Seo,⁴⁴ Mohamed L. Sorrow,^{45,46} Jeff Szer,⁴⁷ Baldeep M. Wirk,⁴⁸ William A. Wood,⁴⁹ and Andrew Artz⁵⁰

¹Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA; ²Center for International Blood and Marrow Transplant Research and

³Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI; ⁴Northwestern Memorial Hospital, Chicago, IL;

⁵Department of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia; ⁶Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA; ⁷Royal Melbourne Hospital, Victoria, VIC, Australia; ⁸Centre Hospitalier Universitaire de Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium; ⁹Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD; ¹⁰Department of Hematology and Oncology, University of Miami, Miami, FL; ¹¹Department of Hematology, University Hospital, Grenoble, France; ¹²Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA; ¹³Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA; ¹⁴Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; ¹⁵Department of Stem Cell Transplantation and Cellular Therapy and ¹⁶Transplant Myeloid Study Group, The University of Texas MD Anderson Cancer Center, Houston, TX; ¹⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; ¹⁸Indiana Blood and Marrow Transplantation, Indianapolis, IN; ¹⁹Mayo Clinic, Jacksonville, FL; ²⁰Texas Transplant Institute, San Antonio, TX; ²¹Department of Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; ²²Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom; ²³Memorial Sloan Kettering Cancer Center, New York, NY; ²⁴Department of Internal Medicine, Mayo Clinic, Minneapolis, MN; ²⁵Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; ²⁶Department of Internal Medicine, University of Kentucky Chandler Medical Center, Lexington, KY; ²⁷Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; ²⁸Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH; ²⁹Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, PA; ³⁰Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ³¹Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR; ³²Blood and Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; ³³Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ³⁴Department of Medicine, University of California San Francisco Medical Center, San Francisco, CA; ³⁵Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; ³⁶Center for Clinical Research Sormland, Uppsala University, Uppsala, Sweden; ³⁷Blood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI; ³⁸Bone Marrow Transplant Program, Henry Ford Hospital, Detroit, MI; ³⁹Division of Hematologic Malignancies and Cellular Therapy, Blood and Marrow Transplant Clinic, Duke University, Durham, NC; ⁴⁰Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ⁴¹Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands; ⁴²Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; ⁴³Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada; ⁴⁴National Cancer Research Center, East Hospital, Kashiwa, Chiba, Japan; ⁴⁵Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ⁴⁶Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; ⁴⁷Department Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, VIC, Australia; ⁴⁸Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA; ⁴⁹Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and ⁵⁰Section of Hematology/Oncology, University of Chicago School of Medicine, Chicago, IL

Key Points

- Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies.
- Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.

Submitted 14 March 2017; accepted 19 June 2017. Prepublished online as *Blood* First Edition paper, 3 July 2017; DOI 10.1182/blood-2017-03-772368.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥ 70 years with hematologic malignancies across the United States. Adults ≥ 70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied. One thousand one hundred and six patients ≥ 70 years underwent HCT across 103 transplant centers. The number and proportion of allografts performed in this population rose markedly over the past decade, accounting for 0.1% of transplants in 2000 to 3.85% ($N = 298$) in 2013. Acute myeloid leukemia and myelodysplastic syndromes represented the most common disease indications. Two-year OS and PFS significantly improved over time (OS: 26% [95% confidence interval (CI), 21% to 33%] in 2000-2007 to 39% [95% CI, 35% to 42%] in 2008-2013, $P < .001$; PFS: 22% [16% to 28%] in 2000-2007 to 32% [95% CI, 29% to 36%] in 2008-2013, $P = .003$). Two-year TRM ranged from 33% to 35% and was unchanged over time ($P = .54$). Multivariable analysis of OS in the modern era of 2008-2013 revealed higher comorbidity by HCT comorbidity index ≥ 3 (hazard ratio [HR], 1.27; $P = .006$), umbilical cord blood graft (HR, 1.97; $P = .0002$), and myeloablative conditioning (HR, 1.61; $P = .0002$) as adverse factors. Over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥ 70 years. Select adults ≥ 70 years with hematologic malignancies should be considered for transplant. (*Blood*. 2017;130(9):1156-1164)

Introduction

Allogeneic hematopoietic cell transplantation (HCT) offers the best potential for prolonged disease control for many hematologic malignancies. Historically, older adults were not considered candidates out of concern for increased toxicity and mortality,¹ thus excluding the majority of hematologic malignancy patients who may have gained benefit. In recent years, the development of reduced-intensity conditioning (RIC) and nonmyeloablative (NMA) regimens,² coupled with improvements in supportive care measures³ and more accurate HLA typing methods,⁴ has broadened the application of HCT to include older adults. As such, 22% of HCT recipients for malignant diseases from 2007 to 2013 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were >60 years of age.⁵

The feasibility of HCT in adults >50 years of age, and even those >65 years, has been detailed in several reports.⁶⁻¹¹ In a registry analysis of patients with acute myeloid leukemia (AML) in first remission or myelodysplastic syndrome (MDS) receiving RIC allogeneic transplants, no significant differences in outcomes were uncovered among HCT recipients aged 40 to 50 years versus those >65 years.⁷ Similar results have been reported in multicenter series from the United States and the European Society for Blood and Marrow Transplantation, where disease status and medical comorbidities, rather than chronological age, appear to predict for outcomes.^{6,8,11}

Although most studies conclude that older age alone should not preclude transplant, very limited data exist regarding patients transplanted in their eighth decade.¹² This population is of particular interest, as it has been shown that for each 5-year increase in age beyond 65 years, the proportion of cancer patients with comorbidity, disability, and/or geriatric syndromes increases by 3% to 5%,^{13,14} prompting recommendations to perform a comprehensive geriatric assessment for all cancer patients in this age group.¹⁵ Further, as the population continues to age, with 50% of all cancers and 70% of cancer mortality occurring in adults ≥ 65 years, the number of patients considered for HCT in their eighth decade will continue to rise.¹⁶

We therefore conducted an observational study of allogeneic HCT recipients ≥ 70 years reported to the CIBMTR between 2000 and 2013 with the aims of describing transplant utilization as well as baseline characteristics, outcomes, and prognostic factors for this understudied cohort of HCT recipients.

Methods

Data sources

The CIBMTR is a research collaboration between the National Marrow Donor Program/Be The Match and the Medical College of Wisconsin. The CIBMTR

represents an international network of transplant centers that submit transplant-related data for patients. It has been collecting HCT outcomes data for >40 years and has an extensive database of detailed patient-, transplant-, and disease-related information with prospectively collected longitudinal data.¹⁷ CIBMTR data are collected in compliance with Health Insurance Portability and Accountability Act regulations and with all applicable federal regulations pertaining to the protection of human research participants, as determined by a continuous review by the National Marrow Donor Program institutional review board and the Medical College of Wisconsin.

The CIBMTR collects 2 levels of data: registration-level data are retrieved from Transplant Essential Data forms, and additional research level data are collected using Comprehensive Report Forms (CRFs). The latter is a subset of the former; patients for whom CRF-level data are collected are chosen through a selection algorithm, as these forms are longer and require more extensive data, including detailed disease information. Thus, the objective of this study included assessing transplant practices and activity in the United States using Transplant Essential Data-level data. Additional analysis with more detailed disease-specific information was performed in a subset of this population as described in statistical section below.

Patient population

Patients aged ≥ 70 years at time of first allogeneic HCT occurring between 2000 and 2013 and reported to the CIBMTR were included. Exclusion criteria included syngeneic donor transplant and patients reported to the CIBMTR who received HCT outside of the United States.

Definitions and outcomes

Disease status at time of transplant followed CIBMTR disease risk classification¹⁸: early disease (acute leukemia in first complete remission, myelodysplastic syndromes with $<5\%$ blasts, or chronic-phase chronic myeloid leukemia [CML]), intermediate disease (second or greater complete remission acute leukemia, accelerated-phase CML), and advanced disease (acute leukemia not in remission, myelodysplastic syndromes with $\geq 5\%$ marrow blasts, or blast-phase CML); lymphomas were classified according to chemotherapy sensitivity (sensitive or resistant at time of transplant). Patients with AML were also described in greater detail using CRF data to report disease characteristics of interest, including frequency of favorable, intermediate, and poor cytogenetic categories and presence or absence of FLT3 mutations. Conditioning regimen intensity followed CIBMTR working definitions (myeloablative vs RIC/NMA)^{19,20}; due to data capture constraints, RIC and NMA were grouped together. Comorbidity was scored using the HCT comorbidity index; recipient HCT-comorbidity index scores have been routinely reported to the CIBMTR on all allogeneic HCT recipients since 2008. Performance status was captured by the Karnofsky Performance Scale (KPS). Disease Risk Index (DRI)²¹ was evaluated in the entire population and categorized in a subset of patients with all available elements. HLA-matched unrelated donors required 8/8 matching at HLA-A, HLA-B, HLA-C, and HLA-DRB1 at high resolution. Mismatched related donors included haploidentical donors as well as single-antigen and allele mismatches

Figure 1. Annual number of HCTs in patients 70 years and older by indication. MPS, myeloproliferative syndrome.

(ie, 7 of 8). Neutrophil engraftment was defined as neutrophil count above 500/ μ L for 3 consecutive days. Graft-versus-host disease (GVHD) was defined as acute GVHD (grades II-IV or III-IV according to maximum organ stage) or chronic GVHD.

The primary outcome for this study was overall survival (OS), defined as death from any cause; patients for whom death was not observed were censored at the time of last follow-up. Transplant-related mortality (TRM) was defined as death in the absence of disease relapse or progression. The composite end point of progression-free survival (PFS) required either disease relapse or progression or death; patients alive without such events were censored at the time of last follow-up. Primary cause of death for each patient was reported by the treating center.

Statistical analysis

Descriptive statistics summarized the baseline patient, disease, and transplant-related characteristics according to two time cohorts during the study period (2000 to 2007, 2008 to 2013). The proportion of transplants performed in patients 70 years of age and older relative to all transplants performed in the United States was computed. Univariate summary measures for all outcomes were calculated and compared over the two time periods. Probabilities of OS and PFS were calculated using the Kaplan-Meier estimator, and comparisons between groups were performed using log-rank and point-wise tests. Probabilities of neutrophil engraftment, GVHD, TRM, and disease relapse/progression were calculated by cumulative incidence function accounting for competing risks. Comparisons of cumulative incidence across time cohorts were performed via Gray's test.

Prognostic factor analysis was performed on 3 patient subsets. The first analysis included all patients ≥ 70 years transplanted between 2008 and 2013 with the intention of focusing on a contemporary cohort of patients with all disease indications who received comorbidity assessment by the HCT-comorbidity index (which was not available prior to 2008). For this subset, a multivariable Cox proportional hazards regression model was built using stepwise variable selection to evaluate patient, disease, and transplant variables associated with OS. The variables analyzed were age (70-74 and ≥ 75 years), gender, HCT-comorbidity index (0-2 and ≥ 3),²² KPS (modeled at $\geq 80\%$ and $< 80\%$), disease, disease status, donor type (HLA-matched sibling, HLA-mismatched related, and HLA matched unrelated donor, divided according to donor age [< 30 and ≥ 30 years] or mismatched unrelated donor, unrelated donor with HLA-matching unknown, and umbilical cord blood), conditioning regimen intensity^{19,20} graft source (bone marrow, mobilized peripheral blood stem cells, and umbilical cord blood), year of transplant, donor-recipient gender match, donor-recipient cytomegalovirus serologic status, and GVHD prophylaxis (calcineurin inhibitor and methotrexate, calcineurin inhibitor and mycophenolate mofetil, and calcineurin inhibitor with other combinations and other regimens).

The second subset analysis explored variables associated with OS and TRM among patients ≥ 70 years with controlled disease entering transplant. This subset included patients with early or intermediate-risk AML (ie, patients in complete remission 1 [CR1] or CR2 as opposed to active disease), MDS with $< 5\%$ blasts, and chemosensitive non-Hodgkin lymphoma (NHL) who

underwent HCT between 2008 and 2013. This more homogenous subset included the most common disease indications for HCT among older adults and enabled analysis of variables associated with TRM without confounding from less common transplant disease indications. Multivariable Cox regression models were constructed by testing the covariates as above with the exception of disease status as all patients in this subset had early or intermediate disease at transplant.

The third subset focused on exploring outcomes by comorbidity and disease status in patients with AML and MDS undergoing transplant between 2008 and 2013. For this subset, probabilities of OS and TRM were calculated as above.

For multivariable analysis performed in the first and second subsets, all covariates associated with outcome at $P < .05$ were retained in the final models and considered significant. Tests of proportionality for each covariate and of interaction between covariates were performed; no violations of proportionality or significant interactions were found. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).

Results

HCT utilization for adults 70 years and older over time

A total of 1106 patients ≥ 70 years underwent first allogeneic HCT in the United States and were reported to the CIBMTR between 2000 and 2013. The absolute number of transplants for adults ≥ 70 years increased substantially over that time, from 5 in 2000 to 283 in 2013. The proportion of allogeneic HCT recipients ≥ 70 years also increased over time, from 0.1% in 2000 to 3.85% in 2013. Further, the absolute number of transplant programs performing allogeneic HCT in patients ≥ 70 years increased from 65 centers in 2000-2007 to 93 centers in 2008-2013. Transplant for AML and MDS accounted for the main indications across time periods (Figure 1).

Patient and HCT characteristics

Baseline patient demographics and transplant characteristics stratified by HCT time period for all patients in the dataset are described in Table 1. The median age at time of HCT was 72 (range, 70-84 years). KPS was $< 80\%$ in 9% of the patients. Comorbidity by HCT-comorbidity index (captured for recipients transplanted from 2008 to 2013) demonstrated high HCT-comorbidity index of ≥ 3 in 46% of patients; 16% had HCT-comorbidity index scores of ≥ 5 . Among patients with available DRI, the majority received transplant with intermediate risk. The donor source shifted from related donors in 51% in the initial time period to 70% unrelated grafts in the later time period,

Table 1. Demographics of patients 70 years and older who received HCT from 2000 to 2013

	2000-2007, n (%)	2008-2013, n (%)	All patients, n (%)
No. of patients	207	899	1106
No. of centers	65	93	103
Age at transplant, y			
Median (range)	72 (70-83)	72 (70-84)	72 (70-84)
70-74	176 (85)	807 (90)	983 (89)
75-79	27 (13)	88 (10)	115 (10)
≥80	4 (2)	4 (<1)	8 (1)
Sex			
Male	151 (73)	629 (70)	780 (71)
Female	56 (27)	270 (30)	326 (29)
KPS			
<80%	17 (8)	87 (10)	104 (9)
≥80%	119 (57)	784 (87)	903 (82)
Missing	71 (34)	28 (3)	99 (9)
HCT-comorbidity index			
0	—	248 (28)	248 (22)
1-2	—	234 (26)	234 (21)
≥3	—	417 (46)	417 (38)
Missing*	207	0	207 (19)
Disease			
AML	103 (50)	496 (55)	599 (54)
ALL	2 (<1)	23 (3)	25 (2)
CLL/PLL	22 (11)	54 (6)	76 (7)
CML	5 (2)	6 (<1)	11 (<1)
MDS/MPS	32 (15)	215 (24)	247 (22)
Other acute leukemia	1 (<1)	8 (<1)	9 (<1)
NHL	23 (11)	90 (10)	113 (10)
Plasma cell disorder/multiple myeloma	10 (5)	2 (<1)	12 (1)
Other malignancies	3 (1)	0	3 (<1)
Severe aplastic anemia	4 (2)	5 (<1)	9 (<1)
PNH	2 (1)	0	2 (<1)
Disease status			
Early disease	45 (22)	355 (39)	300 (27)
Intermediate disease	25 (12)	93 (10)	118 (11)
Advanced disease	48 (23)	230 (26)	278 (25)
NHL sensitive	10 (5)	79 (10)	89 (9)
NHL resistant	6 (3)	10 (1)	16 (1)
Other (unknown/missing/NA)	73 (35)	132 (15)	205 (19)
DRI†			
Low	6 (3)	32 (4)	38 (3)
Intermediate	28 (14)	152 (17)	180 (16)
High	20 (10)	115 (13)	135 (12)
Very high	7 (3)	18 (2)	25 (2)
Other (missing/NA)	146 (71)	582 (65)	728 (66)
Donor type			
Matched related	93 (45)	204 (23)	297 (27)
Mismatched related	13 (6)	67 (7)	80 (7)
Matched unrelated	52 (25)	463 (52)	515 (47)
Mismatched unrelated	12 (6)	68 (8)	80 (7)
Unrelated HLA match unknown	20 (10)	46 (5)	66 (6)
Umbilical cord blood	7 (3)	51 (6)	58 (5)
Missing	10 (5)	0	10 (1)
Unrelated donor age, median (range), y			
18-30	23 (27)	278 (48)	301 (46)
31-40	24 (29)	139 (24)	163 (25)
41-50	21 (25)	96 (17)	117 (18)
51-61	5 (6)	25 (4)	30 (5)
Unknown	11 (13)	39 (7)	50 (8)
Graft source			
Bone marrow	17 (8)	93 (10)	110 (10)
Peripheral blood	183 (88)	755 (84)	938 (85)
Umbilical cord blood	7 (3)	51 (6)	58 (5)

Table 1. (continued)

	2000-2007, n (%)	2008-2013, n (%)	All patients, n (%)
Donor-recipient sex match			
Male-male	95 (46)	388 (43)	483 (44)
Male-female	25 (12)	154 (17)	179 (16)
Female-male	50 (24)	203 (23)	253 (23)
Female-female	30 (14)	98 (11)	128 (12)
Unknown	7 (3)	56 (6)	63 (6)
Donor-recipient CMV status			
Positive-positive	16 (8)	269 (30)	285 (26)
Positive-negative	7 (3)	67 (7)	74 (7)
Negative-positive	37 (18)	292 (32)	329 (30)
Negative-negative	13 (6)	176 (20)	189 (17)
Unknown	134 (65)	95 (11)	229 (21)
Regimen intensity			
Ablative	11 (5)	102 (11)	113 (10)
RIC/NMA	178 (86)	796 (89)	974 (88)
Unknown	18 (9)	1 (<1)	19 (2)
Conditioning regimen			
Flu/Bu ± other	29 (14)	368 (41)	397 (36)
Flu/Mel ± other	35 (17)	137 (15)	172 (16)
Flu/TBI ± other	65 (31)	274 (30)	339 (31)
Bu based	11 (5)	17 (2)	28 (3)
Flu/Cy ± other	26 (13)	40 (4)	66 (6)
TBI/TLI ± other	16 (8)	49 (5)	65 (6)
Other	17 (8)	14 (2)	31 (3)
Unknown	8 (4)	0	8 (<1)

ALL, acute lymphoblastic leukemia; Bu, busulfan; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; Flu/Bu, fludarabine + busulfan; Flu/Mel, fludarabine + melphalan; Flu/TBI, fludarabine + total body irradiation; MPS, myeloproliferative syndrome; NA, not available; PLL, polyclonal lymphocytic leukemia; PNH, paroxysmal nocturnal hemoglobinuria; Flu/Cy, fludarabine + cyclophosphamide; TBI/TLI, total body irradiation or total lymphoid irradiation.

*HCT-comorbidity index was not captured by the CIBMTR registry prior to 2008.

†All elements required to generate the DRI were not available in all patients.

driven mostly by greater use of matched unrelated donors over time. Although most patients received RIC/NMA conditioning regimens, myeloablative regimens were administered to 10% overall. The more widespread use of fludarabine plus busulfan-based regimens signified the largest change in conditioning regimens over time. Increasing numbers of patients entered transplant with controlled disease in the more recent time period.

Supplemental Table A (available on the *Blood* Web site) includes additional disease and transplant-related details regarding AML patients transplanted between 2008 and 2013. In this subset of 120 patients with AML with available information, 70% had intermediate cytogenetics, 85% of patients with available FLT3 status were wild-type, and 69% were in morphologic complete remission at time of transplant.

Outcomes

Unadjusted 1- and 2-year transplant outcome probabilities (neutrophil engraftment, grades II-IV and III-IV acute GVHD, chronic GVHD, TRM, relapse/progression, PFS, and OS) stratified by HCT time period are summarized in Table 2. Two-year PFS improved significantly from 2000-2007 to 2008-2013 (22% [95% confidence interval (CI) 16% to 28%] vs 32% [29% to 36%], $P = .003$), while TRM remained static ($P = .54$ over the entire time period). Two-year OS also improved significantly over time, from 26% [95% CI, 21% to 33%] in 2000-2007% to 39% [95% CI, 35% to 42%] in 2008-2013, $P < .001$ (Figure 2A). Overall and disease-free survival among patients with the most common indications for HCT from 2008 to 2013 and according to DRI in the same period are shown in Figure 2B-E).

Table 2. Univariate analysis of posttransplant outcomes of patients aged 70 years and older and recipients of an allogeneic HCT from 2000 to 2013

	Total cohort prob. (95% CI)	2000-2007 prob. (95% CI)	2008-2013 prob. (95% CI)	P*
Neutrophil engraftment†				
No. evaluated	—	—	890	—
28 d	—	—	92 (90-93)	—
Acute GVHD, grade II-IV				
No. evaluated	427	105	322	.63
100 d	32 (28-37)	31 (23-41)	33 (28-38)	.82
Acute GVHD, grade III-IV				
No. Evaluated	427	105	322	.05
100 d	13 (10-17)	18 (11-26)	12 (9-16)	.13
Chronic GVHD				
No. evaluated	1025	161	864	.94
1 y	32 (30-35)	32 (25-40)	32 (29-36)	.97
2 y	37 (34-40)	35 (28-43)	38 (35-41)	.55
TRM				
No. evaluated	1086	192	894	.77
1 y	25 (23-28)	26 (20-33)	25 (22-28)	.73
2 y	33 (30-36)	35 (28-42)	33 (29-36)	.54
Relapse/progression				
No. evaluated	1086	192	894	.04
1 y	32 (30-35)	38 (31-45)	31 (28-34)	.09
2 y	37 (34-40)	43 (36-50)	35 (32-38)	.04
PFS				
No. evaluated	1086	192	894	.001
1 y	42 (39-45)	36 (29-43)	44 (40-47)	.04
2 y	30 (27-33)	22 (16-28)	32 (29-36)	.003
OS				
No. evaluated	1106	207	899	<.001
1 y	50 (47-53)	42 (35-49)	52 (49-56)	.007
2 y	36 (33-39)	26 (21-33)	39 (35-42)	<.001

Prob., probability.

*P value for significance between the 2000-2007 and 2008-2013 cohorts.

†Neutrophil engraftment was not consistently captured prior to 2008.

The most frequent primary cause of death was relapse/progression of primary disease, which accounted for 46% of deaths. Infection and GVHD were each reported as the primary cause of death in 10%. Cause of death could not be clarified in 22% of the patients.

Prognostic factor analysis in modern cohorts

The first subset analysis focused on all patients ≥ 70 years transplanted between 2008 and 2013. Significant prognostic factors for inferior survival included high comorbidity defined by HCT-comorbidity index ≥ 3 (hazard ratio [HR], 1.27; 95% CI, 1.07-1.51; $P = .006$), receipt of cord blood as a donor source (HR, 1.97; 95% CI, 1.37-2.82; $P = .0002$) relative to HLA matched sibling donor, and use of a myeloablative conditioning regimen (HR, 1.61; 95% CI, 1.25-2.08; $P = .0002$) (Table 3). All other variables tested in the model, including age, disease status, disease, and KPS, were not found to significantly influence survival.

Table 3 highlights variables significantly associated with TRM and OS among the subset of 416 HCT recipients with early or intermediate AML or MDS or chemosensitive NHL transplanted between 2008 and 2013. Female relative to male recipients (HR, 1.30; 95% CI, 1.03-1.65; $P = .029$) and myeloablative conditioning as opposed to RIC/NMA (HR, 1.60; 95% CI, 1.13-2.28; $P = .009$) were associated with higher mortality. Conditioning regimen intensity was the only significant covariate associated with TRM (HR, 2.06; 95% CI, 1.32-3.22; $P = .001$) in this subset.

Supplemental Figure 1A-D demonstrates OS and TRM, respectively, for patients with AML or MDS who underwent transplantation

between 2008 and 2013 based upon both disease risk at time of transplantation (early/intermediate disease vs advanced disease) and also by comorbidity score (ie, HCT < 3 vs ≥ 3). High comorbidity in this population appeared to have a greater adverse impact on patients with advanced or active disease at time of transplant as opposed to patients with early or intermediate disease (ie, in remission) at the time of transplant.

Discussion

In the current observational study, we report on the utilization, characterization and prognostic factors associated with allogeneic HCT in adults ≥ 70 years. Our findings, derived from a large national cohort of patients transplanted in the United States over the last decade, demonstrate that the absolute number and proportion of allogeneic transplants performed for adults in their eighth decade has risen steadily on a yearly basis since 2000, such that patients ≥ 70 years now represent nearly 4% of allogeneic HCT recipients.

Several factors spurred the increase in transplant volume for this population. The majority of growth was in fact due to increasing numbers of patients with early or intermediate-risk AML or MDS as defined by the CIBMTR (ie, AML in CR1 or greater; MDS with $< 5\%$ blasts) transplanted since 2008. Greater utilization of HCT for MDS beginning after 2010 coincides with the decision in the United States to cover this disease indication for Medicare beneficiaries

Figure 2. Allogeneic HCT outcomes in adults 70 years and older. (A) OS after HCT in patients ≥ 70 years by year of transplant (2000-2007 vs 2008-2013). (B) Disease-free survival after HCT in patients ≥ 70 years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (C) OS after HCT in patients ≥ 70 years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (D) Disease-free survival after HCT in patients ≥ 70 years from 2008 to 2013 according to DRI. (E) OS after HCT in patients ≥ 70 years from 2008 to 2013 according to DRI.

participating in an approved clinical study through the Center for Medicare and Medicaid Services Coverage with Evidence Development.²³ Additionally, the increasing use of unrelated donors (and, to some extent, haploidentical or cord blood donor stem cell sources) relative to sibling donors fueled transplant growth by substantially expanding donor availability. Perhaps the most important yet difficult to measure factor is the societal changes that have prompted physician and patient willingness to consider transplant. Similar trends in uptake for older patients have been reported in autologous transplants where donor sources are irrelevant, as well as in solid organ transplantation.^{24,25}

Despite increased utilization of HCT for this older adult population, the relatively small number of allogeneic transplants confirms reports by others^{26,27} that the vast majority of adults aged ≥ 70 years

with transplant-eligible hematologic malignancies are not undergoing HCT. For example, according to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, there are ~ 3000 new cases of AML diagnosed per year in adults aged 70 to 79 years in the United States (<http://seer.cancer.gov/>). Our data reveal that only 253 AML patients aged ≥ 70 years underwent allogeneic HCT between 2012 and 2013, representing only 4% of the population of newly diagnosed AML patients in their eighth decade of life. Transplant was even more rarely pursued in this age group for other disease indications, such as NHL (n = 113) and acute lymphoblastic leukemia (n = 25).

The lack of transplant outcome data in this age group has been a major impediment and previously has been restricted to reports

Table 3. Multivariate models for overall mortality (1 – OS) and TRM in patients aged 70 years and older who received an allogeneic HCT

Effect	No.	HR	95% CI	P
Overall mortality				
HCT-comorbidity index				
0-2	479	1.000	—	—
≥3	415	1.269	1.070, 1.504	.0061
Donor type				
HLA-matched, related	202	1.000	—	—
HLA-mismatched, related	67	1.209	0.848, 1.724	.2932
HLA-matched, URD < = 30 y old	233	0.933	0.726, 1.199	.5874
HLA-matched, URD > 30 y old	210	1.144	0.898, 1.457	.2754
HLA-matched, URD of unknown age	19	0.838	0.425, 1.649	.6080
HLA-mismatched, URD	67	1.324	0.945, 1.854	.1025
HLA matching unknown, URD	45	1.178	0.782, 1.775	.4340
UCB	51	1.963	1.372, 2.809	.0002
Conditioning intensity				
RIC/NMA	791	1.000	—	—
Overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL				
Sex				
Male	359	1.00	—	—
Female	165	1.30	1.03-1.65	.03
Conditioning intensity				
RIC/NMA	473	1.00	—	—
MA	50	1.60	1.13-2.28	.009
TRM for patients with early/intermediate AML/MDS and chemosensitive NHL				
Conditioning intensity				
RIC/NMA	473	1.00	—	—
MA	50	2.06	1.32-3.22	.001

The first model for overall mortality in a population from 2008 to 2013 and all hematologic malignancies. The second multivariate analysis includes models for overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL and TRM for a subset of patients with early and intermediate AML and MDS who received an allogeneic HCT from 2008 to 2013.

MA, myeloablative; UCB, umbilical cord blood; URD, unrelated donor.

*Donor type variable was tested with 7 degrees of freedom and divided the group of matched unrelated donor according to donor age divided at the median.

including small numbers of these patients.^{11,27} We found that transplant survival has significantly improved over time for this older adult population, with 2-year PFS and OS estimates of 32% (95% CI, 29% to 36%) and 39% (95% CI, 35% to 42%), respectively, for HCT recipients transplanted in the more recent era of 2008-2013. As TRM and severe acute GVHD did not change over time, improvements were likely mediated in part by transplant in patients with less advanced disease. Consistent with this, a greater proportion of patients entered transplant with earlier-risk disease (recognizing many were missing disease risk in earlier years), and improvements occurred in PFS and cumulative incidence of disease relapse.

Given the methodological issues and biases associated with retrospectively comparing treatment approaches, prospective studies are required to effectively evaluate HCT versus non-HCT therapies in older adults for each disease indication. Few studies report outcomes of patients ≥70 years after nontransplant treatment to benchmark these results, and lack of consistent patient health information reported in these studies hinders identification of transplant-eligible subsets. In a population study of AML from the Netherlands, 69% of patients ≥70 years received some form of chemotherapy, but no patients were allografted, resulting in dismal 1- and 5-year survival rates of 15% and 2%, respectively, for patients diagnosed between 2007 and 2012.²⁸ Thus, our study outcomes for AML patients transplanted between 2008 and 2013, revealing 2-year PFS and OS of 36% and 38%, respectively, appear extremely encouraging and suggest that select older patients achieve a substantial disease and survival benefit after HCT.

Concerns regarding treatment-related morbidity and mortality likely account for reluctance to offer transplant to older patients. Our findings that TRM has remained stable over the decade, with 2-year estimates at 30% to 35%, is similar to the findings of the registry

analysis, where 2-year TRM ranged from 25% to 39% in adults ≥40 years with AML and MDS following RIC HCT, without significant differences across age groups.⁷ Registry summaries inclusive of heterogeneous disease status, donor type, and conditioning regimen may be less favorable than institutional protocol reports of more selected patients yet reflect present population-based practice patterns and results. Although supportive care for hematologic malignancy and transplant recipients has improved considerably in recent years, so much so as to allow the application of allogeneic HCT to patients ≥70 years, appreciable TRM remains a barrier to transplant utilization and success in this group. Impairments in adaptive immune response with aging are accentuated in the allogeneic transplant setting and likely contribute to the relatively high rates of transplant-related morbidity and mortality in older patients.²⁹ Strategies to overcome thymic impairments with aging and allogeneic transplant are of considerable interest.³⁰ Higher rates of TRM in those patients 70 years and older with advanced disease and high comorbidity suggest that transplant should be pursued with particularly caution in such patients.

To reduce TRM, we must consider improvements in patient selection and further refine the transplant process to allow for less toxicity and morbidity in older adults. Similar to others,¹¹ we found that inferior survival was associated with high comorbidity, albeit with only a modest effect (HR, 1.27; 95% CI, 1.07-1.51). Patients ≥75 years did not fare significantly worse than those 70 to 74 years of age. Therefore, age alone or moderate degrees of comorbidity are insufficient to determine transplant eligibility. Enhanced discrimination may be obtained with the use of geriatric assessment prior to HCT.³¹ Geriatric assessment for evaluation and guided interventions warrant additional research to abrogate morbidity and mortality.^{15,32} More precise risk stratification for TRM, if not survival, may paradoxically

expand the number of older patients eligible for transplant by delineating a larger pool of patients with acceptable transplant risks.

Similar to younger patients, disease relapse remains the primary cause of death in older transplant recipients. However, more intensive transplant conditioning via myeloablative regimens was associated with worse OS in the whole cohort and in the subset of early/intermediate AML/MDS and chemosensitive NHL. While new disease scoring systems such as the DRI- and minimal residual disease–based assessments have been used to evaluate relapse risk in younger HCT patients, the importance of these tools in older patients is less established.^{21,33} For example, independent of the DRI, older patients fare worse, and minimal residual disease measures have a less pronounced effect on relapse after NMA transplant for AML and have not been shown to affect survival in this population.³³ This likely reflects the adverse biology of disease in older age in that even after adjustments for adverse disease features, older adults routinely demonstrate outcomes significantly inferior to those of younger adults.^{34,35} This underscores the need to move to transplant expeditiously after initial treatment–induced response as well as to explore posttransplant maintenance and adoptive immunotherapy approaches following RIC or NMA allogeneic HCT in older adults.

In summary, the utilization of allogeneic HCT in adults aged ≥ 70 years with hematologic malignancies has markedly increased over the past decade. Nearly 40% of adults in this age group are alive at 2 years following transplant, suggesting that this approach is feasible, offers promising disease control, and should be considered more frequently for patients in their eighth decade with transplant-eligible diseases.

Acknowledgments

The CIBMTR is supported primarily by National Institutes of Health public health service grant/cooperative agreement 5U24-CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases; grant/cooperative agreement 5U10HL069294 from the National Heart, Lung, and Blood Institute and the National Cancer Institute; contract HHS250201200016C with Health Resources and Services Administration (US Department of Health and Human Services); grants N00014-15-1-0848 and N00014-16-1-2020 from the Office of Naval Research. This work was also funded by grants from Actinium Pharmaceuticals, Inc.,* Alexion, and Amgen, Inc.*; by an anonymous donation to the Medical College of Wisconsin; by Astellas Pharma US, AstraZeneca, Atara Biotherapeutics, Inc., Be the Match Foundation, Bluebird Bio,

Inc.,* Bristol Myers Squibb Oncology,* Celgene Corporation,* Cellular Dynamics International, Inc., Cerus Corporation, Chimerix, Inc.,* the Fred Hutchinson Cancer Research Center, Gamida Cell Ltd., Genentech, Inc., Genzyme Corporation, Gilead Sciences, Inc., Health Research, Inc., Roswell Park Cancer Institute, HistoGenetics, Inc., Incyte Corporation, Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals, Inc.,* the Jeff Gordon Children's Foundation, The Leukemia & Lymphoma Society, Medac, GmbH, MedImmune, The Medical College of Wisconsin, Merck & Co, Inc.,* Mesoblast,* MesoScale Diagnostics, Inc., Miltenyi Biotec, Inc.,* National Marrow Donor Program, Neovii Biotech NA, Inc., Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, Optum Healthcare Solutions, Inc., Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Co, Ltd., Japan, PCORI, Perkin Elmer, Inc., Pfizer, Inc., Sanofi US,* Seattle Genetics,* Spectrum Pharmaceuticals, Inc.,* St. Baldrick's Foundation, Sunesis Pharmaceuticals, Inc.,* Swedish Orphan Biovitrum, Inc., Takeda Oncology, Telomere Diagnostics, Inc., the University of Minnesota, and Wellpoint, Inc.* (asterisk indicates corporate members).

The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government.

Authorship

Contribution: L.M., A.A., M.C.P., R.B., M.M., X.Z., K.A., M.A., K.K.B., A. Bajel, F.B., M.B., A. Beitinjane, J.-Y.C., M.C., Y.-B.C., S. Chhabra, S. Ciurea, E.C., A.D., J.E., J.F., C.O.F., H.C.F., R.P.G., S.G., S.K.H., G.C.H., V.H., A.J., H.L., M.R.L., R. Martino, R. Maziarz, P.M., T.N., R.O., R.F.O., A.P., E.P., A.R.R., D.R., B.N.S., H.C.S., M. Sabloff, M. Seftel, S.S., M.L.S., J.S., B.M.W., and W.A.W. designed research; L.M., A.A., M.C.P., R.B., M.M., and X.Z. performed research; L.M., A.A., M.C.P., R.B., M.M., X.Z., K.A., M.A., K.K.B., A. Bajel, F.B., M.B., A. Beitinjane, J.-Y.C., M.C., Y.-B.C., S. Chhabra, S. Ciurea, E.C., A.D., J.E., J.F., C.O.F., H.C.F., R.P.G., S.G., S.K.H., G.C.H., V.H., A.J., H.L., M.R.L., R. Martino, R. Maziarz, P.M., T.N., R.O., R.F.O., A.P., E.P., A.R.R., D.R., B.N.S., H.C.S., M. Sabloff, M. Seftel, S.S., M.L.S., J.S., B.M.W., and W.A.W. analyzed and interpreted data; R.B., M.M., and X.Z. performed statistical analysis; and L.M., A.A., M.C.P., R.B., M.M., and X.Z. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Lori Muffy, Stanford University, 300 Pasteur Dr, H0144B, Stanford, CA 94305; e-mail: lmuffy@stanford.edu.

References

- Armitage JO. Bone marrow transplantation. *N Engl J Med*. 1994;330(12):827-838.
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*. 2001;97(11):3390-3400.
- van Besien K, Artz A, Stock W. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? *Leukemia*. 2005;19(1):31-33.
- Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood*. 2007;110(13):4576-4583.
- D'Souza A, Zhu X. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2016. Available at: <https://www.cibmtr.org>. Accessed 1 February 2017.
- Chevallier P, Szydlo RM, Blaise D, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. *Biol Blood Marrow Transplant*. 2012;18(2):289-294.
- McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. *J Clin Oncol*. 2010;28(11):1878-1887.
- Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. *J Clin Oncol*. 2008;26(32):5183-5191.
- Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic

- syndromes or secondary acute myeloid leukemia. *J Clin Oncol*. 2010;28(3):405-411.
10. Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. *J Clin Oncol*. 2005;23(15):3439-3446.
 11. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA*. 2011;306(17):1874-1883.
 12. Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. *Biol Blood Marrow Transplant*. 2017;23(1):44-52.
 13. Koroukian SM, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. *J Clin Oncol*. 2006;24(15):2304-2310.
 14. Gale CR, Cooper C, Sayer AA. Prevalence of frailty and disability: findings from the English Longitudinal Study of Ageing. *Age Ageing*. 2015;44(1):162-165.
 15. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol*. 2014;32(24):2595-2603.
 16. Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. *Nat Clin Pract Oncol*. 2006;3(2):86-93.
 17. Pasquini MC, Wang Z, Horowitz M, et al. 2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders. In: Everly JE, Terazaki PI, eds. *Clinical Transplants 2013*. Los Angeles: The Terasaki Foundation Laboratory; 2014:187-198.
 18. American Society for Blood and Marrow Transplant. ASBMT RFI 2016: Disease Classifications Corresponding to CIBMTR Classifications. Available at: http://asbmt.org/sites/default/files/asbmt_admin/ASBMT_RFI_2016_CIBMTR_Diseases.pdf. Accessed 1 February 2017.
 19. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant*. 2009;15(12):1628-1633.
 20. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant*. 2009;15(3):367-369.
 21. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. *Blood*. 2014;123(23):3664-3671.
 22. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106(8):2912-2919.
 23. Atallah E, Horowitz MM, Logan B, et al. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age. *Blood*. 2015;126(23):193.
 24. Abecassis M, Bridges ND, Clancy CJ, et al. Solid-organ transplantation in older adults: current status and future research. *Am J Transplant*. 2012;12(10):2608-2622.
 25. Auner HW, Garderet L, Kröger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. *Br J Haematol*. 2015;171(4):453-462.
 26. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. *Haematologica*. 2012;97(12):1916-1924.
 27. Brunner AM, Kim HT, Coughlin E, et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. *Biol Blood Marrow Transplant*. 2013;19(9):1374-1380.
 28. Dinmohamed AG, Visser O, van Norden Y, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. *Leukemia*. 2016;30(1):24-31.
 29. Krenger W, Blazar BR, Holländer GA. Thymic T-cell development in allogeneic stem cell transplantation. *Blood*. 2011;117(25):6768-6776.
 30. Chaudhry MS, Velardi E, Malard F, van den Brink MR. Immune reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus. *J Immunol*. 2017;198(1):40-46.
 31. Muffy LS, Boulukos M, Swanson K, et al. Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. *Biol Blood Marrow Transplant*. 2013;19(3):429-434.
 32. Artz AS, Chow S. Hematopoietic cell transplantation in older adults: deciding or decision-making? *Bone Marrow Transplant*. 2016;51(5):643-644.
 33. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. *Leukemia*. 2015;29(1):137-144.
 34. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. *J Clin Oncol*. 2012;30(36):4515-4523.
 35. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.

2017 130: 1156-1164

doi:10.1182/blood-2017-03-772368 originally published
online July 3, 2017

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Lori Muffy, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K. Ballen, Ashish Bajel, Frederic Baron, Mino Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O. Freytes, Henry C. Fung, Robert Peter Gale, Sergio Giral, Shahrukh K. Hashmi, Gerhard C. Hildebrandt, Vincent Ho, Ann Jakubowski, Hillard Lazarus, Marlise R. Luskin, Rodrigo Martino, Richard Maziarz, Philip McCarthy, Taiga Nishihori, Rebecca Olin, Richard F. Olsson, Attaphol Pawarode, Edward Peres, Andrew R. Rezvani, David Rizzieri, Bipin N. Savani, Harry C. Schouten, Mitchell Sabloff, Matthew Seftel, Sachiko Seo, Mohamed L. Sorrow, Jeff Szer, Baldeep M. Wirk, William A. Wood and Andrew Artz

Updated information and services can be found at:

<http://www.bloodjournal.org/content/130/9/1156.full.html>

Articles on similar topics can be found in the following Blood collections

[Transplantation](#) (2335 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>